Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.
Sonoma Pharma made more money than ever before and finally became profitable on an adjusted basis—meaning the company is growing its sales and controlling its costs better. When a company hits these milestones, it shows the business is getting stronger, so watch whether they keep this momentum going in future quarters.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.